Designing multi-target drugs for the treatment of major depressive disorder
- 19 May 2023
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 18 (6) , 643-658
Abstract
Major depressive disorders (MDD) pose major health burdens globally. Currently available medications have their limitations due to serious adverse effects, long latency periods as well as resistance. Considering the highly complicated pathological nature of this disorder, it has been suggested that multitarget drugs or multi-target-directed ligands (MTDLs) may provide long-term therapeutic solutions for the treatment of MDD. In the current review, recent lead design and lead modification strategies have been covered. Important investigations reported in the last ten years (2013-2022) for the preclinical development of MTDLs (through synthetic medicinal chemistry and biological evaluation) for the treatment of MDD were discussed as case studies to focus on the recent design strategies. The discussions are categorized on the basis of pharmacological targets. Based on these important case studies, the challenges involved in different design strategies were discussed in detail. Even though large variations were observed in the selection of pharmacological targets, some potential biological targets (NMDA, melatonin receptors) are required to be explored extensively for the design of MTDLs. Similarly, apart from structure activity relationship (SAR), in silico techniques such as multitasking cheminformatic modeling, molecular dynamics simulation and virtual screening should be exploited to a greater extent.Keywords
Funding Information
- Foundation for Science and Technology within the Ministry of Science, Technology and Higher Education in Portugal
This publication has 105 references indexed in Scilit:
- Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010PLOS Medicine, 2013
- Regulation of AMPA receptor surface trafficking and synaptic plasticity by a cognitive enhancer and antidepressant moleculeMolecular Psychiatry, 2012
- Quinoline- and isoquinoline-sulfonamide derivatives of LCAP as potent CNS multi-receptor—5-HT1A/5-HT2A/5-HT7 and D2/D3/D4—agents: The synthesis and pharmacological evaluationBioorganic & Medicinal Chemistry, 2012
- VilazodoneCNS Drugs, 2011
- The role of serotonin receptor subtypes in treating depression: a review of animal studiesPsychopharmacology, 2010
- A systematic review of duloxetine and venlafaxine in major depression, including unpublished dataActa Psychiatrica Scandinavica, 2010
- Effect of 5-HT7 antagonist SB-269970 in the modulation of working and reference memory in the ratBehavioural Brain Research, 2008
- 7-Arylpiperazinylalkyl and 7-tetrahydroisoquinolinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and some of their purine-2,6,8-trione analogs as 5-HT1A, 5-HT2A, and 5-HT7 serotonin receptor ligandsBioorganic & Medicinal Chemistry, 2007
- Rolipram: A specific phosphodiesterase 4 inhibitor with potential antipsychotic activityNeuroscience, 2007
- New approaches to antidepressant drug discovery: beyond monoaminesNature Reviews Neuroscience, 2006